NEWS RELEASE

2020.10.21

Inventiva announces FDA has granted Breakthrough Therapy designation to lanifibranor in NASH

Inventiva (France) announced on 12 October, 2020, FDA haas granted Breakthrough Therapy designation to lanifibranor for the treatment of NASH.

 

For detailed information, see the below URL.

http://www.globenewswire.com/news-release/2020/10/12/2107044/0/en/Inventiva-receives-FDA-Breakthrough-Therapy-designation-for-lead-drug-candidate-lanifibranor-in-NASH.html

 

Lanifibranor is a PPAR agonist with moderate and well-balanced activity on the three PPAR isoforms (a, g, σ) This compound is also currently undergoing Phase 2 trials.
We are looking forward to future clinical results.